Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.
Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E, Chauncey T, Doney K, Flowers ME, Hansen J, Martin PJ, Nash RA, Petersdorf E, Radich J, Sale G, Sandmaier BM, Storb R, Wade J, Witherspoon R, Appelbaum FR. Jurado M, et al. Biol Blood Marrow Transplant. 2002;8(3):161-9. doi: 10.1053/bbmt.2002.v8.pm11939606. Biol Blood Marrow Transplant. 2002. PMID: 11939606 Free article. Clinical Trial.
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR. Deeg HJ, et al. Among authors: hansen ja. Blood. 2002 Aug 15;100(4):1201-7. doi: 10.1182/blood-2002-02-0527. Blood. 2002. PMID: 12149198 Free article. Clinical Trial.
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, Heimfeld S, Flowers ME, Anasetti C, Doney KC, Hansen JA, Kiem HP, Nash RA, O'Donnell PV, Radich JP, Sandmaier BM, Scott BL, Sorror ML, Warren EH, Witherspoon RP, Woolfrey A, Appelbaum FR, Storb R. Deeg HJ, et al. Among authors: hansen ja. Biol Blood Marrow Transplant. 2006 May;12(5):573-84. doi: 10.1016/j.bbmt.2005.12.036. Biol Blood Marrow Transplant. 2006. PMID: 16635793 Free article. Clinical Trial.
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia.
Storb R, Pepe M, Deeg HJ, Anasetti C, Appelbaum FR, Bensinger W, Buckner CD, Cliff RA, Doney K, Hansen J, et al. Storb R, et al. Blood. 1992 Jul 15;80(2):560-1. Blood. 1992. PMID: 1627810 Free article. Clinical Trial. No abstract available.
Marrow grafting for acute leukemia: results and future treatment strategies.
Storb R, Buckner CD, Clift RA, Appelbaum FR, Doney KC, Martin P, Anasetti C, Hansen J, Sanders JE, Petersen FB, et al. Storb R, et al. Haematol Blood Transfus. 1990;33:629-35. doi: 10.1007/978-3-642-74643-7_114. Haematol Blood Transfus. 1990. PMID: 2182453 Review. No abstract available.
568 results